Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ
Tytuł pozycji:

Monitoring of plexiform neurofibroma in children and adolescents with neurofibromatosis type 1 by [ 18 F]FDG-PET imaging. Is it of value in asymptomatic patients?

Tytuł :
Monitoring of plexiform neurofibroma in children and adolescents with neurofibromatosis type 1 by [ F]FDG-PET imaging. Is it of value in asymptomatic patients?
Autorzy :
Azizi AA; Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria.
Slavc I; Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria.
Theisen BE; Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria.
Rausch I; Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, Austria.
Weber M; Division of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria.
Happak W; Department of Surgery, Medical University of Vienna, Vienna, Austria.
Aszmann O; Department of Surgery, Medical University of Vienna, Vienna, Austria.
Hojreh A; Division of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria.
Peyrl A; Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria.
Amann G; Department of Clinical Pathology, Medical University of Vienna, Vienna, Austria.
Benkoe TM; Department of Surgery, Medical University of Vienna, Vienna, Austria.
Wadsak W; Division of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria.
Kasprian G; Division of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria.
Staudenherz A; Division of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria.
Hacker M; Division of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria.
Traub-Weidinger T; Division of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria.
Pokaż więcej
Źródło :
Pediatric blood & cancer [Pediatr Blood Cancer] 2018 Jan; Vol. 65 (1). Date of Electronic Publication: 2017 Aug 03.
Typ publikacji :
Clinical Trial; Journal Article
Język :
English
Imprint Name(s) :
Original Publication: Hoboken, N.J. : John Wiley, c 2004-
MeSH Terms :
Positron-Emission Tomography*
Fluorodeoxyglucose F18/*administration & dosage
Neurofibroma, Plexiform/*diagnostic imaging
Neurofibromatosis 1/*diagnostic imaging
Adolescent ; Adult ; Child ; Child, Preschool ; Female ; Humans ; Male
Contributed Indexing :
Keywords: [18F]FDG-PET; children; malignant peripheral nerve sheath tumour; neurofibromatosis type 1; plexiform neurofibroma
Substance Nomenclature :
0Z5B2CJX4D (Fluorodeoxyglucose F18)
Entry Date(s) :
Date Created: 20170804 Date Completed: 20171129 Latest Revision: 20171129
Update Code :
20210210
DOI :
10.1002/pbc.26733
PMID :
28771999
Czasopismo naukowe
Purpose: About 10% of patients with neurofibromatosis type 1 (NF-1) develop malignant peripheral nerve sheath tumours (MPNST) mostly arising in plexiform neurofibroma (PN); 15% of MPNST arise in children and adolescents. 2-[ 18 F]fluoro-2-deoxy-d-glucose ([ 18 F]FDG)-PET (where PET is positron emission tomography) is a sensitive method in differentiating PN and MPNST in symptomatic patients with NF-1. This study assesses the value of [ 18 F]FDG-PET imaging in detecting malignant transformation in symptomatic and asymptomatic children with PN.
Methods: Forty-one patients with NF-1 and extensive PN underwent prospective [ 18 F]FDG imaging from 2003 to 2014. Thirty-two of the patients were asymptomatic. PET data, together with histological results and clinical course were re-evaluated retrospectively. Maximum standardised uptake values (SUVmax) and lesion-to-liver ratio were assessed.
Results: A total of 104 examinations were performed. Mean age at first PET was 13.5 years (2.6-22.6). Eight patients had at least one malignant lesion; four of these patients were asymptomatic. Two of four symptomatic patients died, while all patients with asymptomatic malignant lesions are alive. All malignant tumours could be identified by PET imaging in both symptomatic and asymptomatic patients. All lesions judged as benign by [ 18 F]FDG imaging and clinical judgment were either histologically benign if removed or remained clinically silent during follow-up. SUVmax of malignant and benign lesions overlapped, but no malignant lesion showed FDG uptake ≤3.15. Asymptomatic malignant lesions were detected with a sensitivity of 100%, a negative predictive value of 100% and a specificity of 45.1%.
Conclusion: Malignant transformation of PN also occurs in asymptomatic children and adolescents. Detection of MPNST at early stages could increase the possibility of oncologically curative resections.
(© 2017 Wiley Periodicals, Inc.)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies